Spots of blood after bowel movements, stomach aches, and protracted episodes of diarrhea may be symptoms of early-onset colorectal cancer, which is increasingly diagnosed in young adults who are ineligible for colonoscopies.
The most concerning early indicator of colon cancer is rectal bleeding, which is taboo to talk about outside of the bathroom.
According to Dr. Matthew Kalady in a recent NBC News article, head of the division of colon and rectal surgery at the Ohio State University Comprehensive Cancer Center, "It can be difficult or embarrassing to talk about." However, he added, "the reality is that everyone deals with something like this," and it's crucial to know what's typical and what isn't.
5,075 people with early-onset colorectal cancer were included in the new study from Washington University School of Medicine in St. Louis, which was published Thursday in the Journal of the National Cancer Institute.
The intention was to identify symptoms that could serve as warning signs for colorectal cancer, a condition that has been on the rise in younger individuals in recent years but whose alarmingly high rate of late-stage diagnosis warrants concern. The percentage of colorectal cancer diagnoses involving individuals under the age of 55 quadrupled from 1995 to 2019, from 11% to 20%, according to the American Cancer Society.
Up to two years before a colon cancer diagnosis, the current study identified four different signals:
Anemia due to iron deficiency.
At least one of the symptoms, which could have started up to two years prior to a diagnosis, was experienced by participants.
However, a colonoscopy is only advised at or after the age of 45. This implies that patients may have symptoms for a long time before seeking medical attention or receiving a colon cancer diagnosis, which is treatable if discovered early.
The study's lead author, Dr. Cassandra Fritz, an assistant professor of medicine in the division of gastrointestinal at the Washington University School of Medicine, said, "As patients, we kind of brush these things away."
At least one of such symptoms was present in nearly half of the study subjects three months before their diagnoses. Additional symptoms increased the likelihood of a cancer diagnosis.
The study, according to fellow author Yin Cao, an associate professor of surgery in the department of public health sciences at Washington University School of Medicine, indicates an "alarming problem" for young adults and the medical professionals who treat them. “Young folks need to be aware of these indicators”, Cao stated in an interview, and “this is the message we are making loud and clear.”
Committed to Saving Lives by Improving At-Home Cancer Detection
A non-invasive, quick, easy, and accurate colorectal detection test is available from Mainz Biomed (NASDAQ:MYNZ). Stool tests are more accurate than blood tests and may be performed in the comfort of your own home, making them a more practical choice.
In addition to early colon cancer detection, on May 10th Mainz Biomed announced a partnership with Microba Life Sciences for the Development of PancAlert. The combination of DNA and microbiome biomarkers has the potential to improve the technical profile of a novel pancreatic cancer screening test. A collaborative research initiative is underway to identify disease-specific microbiome biomarkers. With ColoAlert already out in the market, PancAlert looks to be another monumental tool helping savr lives from pancreatic cancer.
The company's core product, ColoAlert, is an at-home colorectal cancer (CRC) screening kit with high sensitivity and specificity. Patients are given a basic kit that includes directions, a stool collector, and mailing instructions so they can mail the kit back to their local lab for testing and results.
This non-invasive test can identify malignancies earlier than fecal occult blood tests (FOBT) by analyzing tumor DNA.
ColoAlert, a stool test that uses PCR technology, finds more cases of colorectal cancer than traditional stool tests and enables early detection. Through a network of top independent laboratories, corporate health initiatives, and direct sales, this screening test is CE marked and is commercially available in a number of European countries.
To receive commercial approval in the US, ColoAlert will be examined in the FDA-registered trial "ReconAAsense." Once licensed in the United States, the Company's commercial objective is to build scalable distribution across the nation through a cooperative partner program with local and national laboratory service providers.
For the processing of the ColoAlert PCR test kit, Mainz Biomed (NASDAQ:MYNZ) has expanded its network of lab partners to include Eurofins GeLaMed. A division of the global laboratory corporation Eurofins Scientific, which does 450 million tests annually and employs over 61,000 people in 61 nations, is Eurofins GeLaMed. Germany is home to four of its locations.
Eurofins GeLaMed offers cutting-edge diagnostics in human genetics, medical microbiology, laboratory medicine, and molecular diagnostics across eleven medical specialties. The more than 500 staff of GeLaMed process more than 15,000 orders daily and offer more than 2,000 analytical procedures from their portfolios in laboratory medicine and microbiology, all under the supervision of medical specialists.
Marcus Cholewa, Director of Clinical Diagnostics for Eurofins Business Line in DACH, expressed enthusiasm for the partnership between Mainz Biomed and Eurofins GeLaMed because Eurofins consistently offers the highest levels of quality, customer service, and the most thorough testing methodologies. Additionally, he said that Eurofins has a track record of offering innovative and high-quality diagnostic testing solutions, and that by collaborating, they could be able to detect colorectal cancer (CRC) and give patients individualized information to help them manage their health.
In order to raise awareness of the importance of early screening for CRC identification and prevention, Mainz Biomed (NASDAQ:MYNZ) will support physician and patient education programs during March Colorectal Cancer Awareness Month and Eurofins GeLaMed will provide ColoAlert at its testing locations.
Additionally, Mainz Biomed has expanded its network of lab partners across Europe and a few overseas markets by including the Instituto de Microecologia in Madrid.
For more than 60 years, the Instituto de Microecologia has been a leader in the study of the microbiota and food sensitivity, emphasizing the importance of intestinal health through microbiological investigation, microbiota profile diagnosis, and specialized health indicators. The company's ongoing expansion in Europe may be seen in Mainz Biomed's entry into the market and commercialization in Spain and Portugal.
Visit this link to learn more about Mainz Biomed (NASDAQ:MYNZ) and its initiatives.
1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.
2) The Article was issued on behalf of and sponsored by, Mainz Biomed NV. Market Jar Media Inc. has or expects to receive from Mainz Biomed NV’s Digital Marketing Agency of Record (Native Ads Inc.) seventy three thousand three hundred forty USD for 17 days (13 business days).
3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.
5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.
6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Mainz Biomed NV’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Mainz Biomed NV’s industry; (b) market opportunity; (c) Mainz Biomed NV’s business plans and strategies; (d) services that Mainz Biomed NV intends to offer; (e) Mainz Biomed NV’s milestone projections and targets; (f) Mainz Biomed NV’s expectations regarding receipt of approval for regulatory applications; (g) Mainz Biomed NV’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Mainz Biomed NV’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Mainz Biomed NV’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Mainz Biomed NV’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Mainz Biomed NV’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Mainz Biomed NV’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Mainz Biomed NV to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Mainz Biomed NV’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Mainz Biomed NV’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Mainz Biomed NV’s business operations (e) Mainz Biomed NV may be unable to implement its growth strategy; and (f) increased competition.
Except as required by law, Mainz Biomed NV undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Mainz Biomed NV nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Mainz Biomed NV nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.
7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Mainz Biomed NV or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Mainz Biomed NV or such entities and are not necessarily indicative of future performance of Mainz Biomed NV or such entities.